Thomas Pulliam

Dr Thomas Pulliam is a postdoctoral research fellow in the lab of Professor Lisa Butler where he undertakes prostate cancer research including treatment response prediction, testing the efficacy of novel drugs, spatial multiomics, nutrition/diet studies, and lipid metabolism. Dr Pulliam recieved his PhD in Cell and Molecular Biology from the Univeristy of Houston in 2021. He conducted his postdoctoral training at MD Anderson Cancer Center in Houston, Texas where he studied the interaction of androgen receptor (AR) signaling, metabolism, and angiogensis in advanced stage prostate cancer. He also aided in the development of novel inhibitors of Calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2), an AR regulated gene shown to drive prostate cancer progression through metabolic adaptation. Cancer Cell Biology, Cancer Therapy, Medical biochemistry - lipids, Cell Metabolism, Endocrinology & Metabolism, Clinical nutrition

[2025] Lin, C., Pulliam, T. L., Han, J. J., Xu, J., Recio, C. V., Wilkenfeld, S. R., . . . Frigo, D. E. (2025). Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer. Cell Reports, 44(6), 115792. [2024] Awad, D., Cao, P. H. A., Pulliam, T. L., Spradlin, M., Subramani, E., Tellman, T. V., . . . Frigo, D. E. (2024). Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity.. Cancer research, 84(5), 703-724.